A Network Meta-analysis of the Efficacy and Side Effects of UDCA-based Therapies for Primary Sclerosing Cholangitis

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Sep 18

PMID 26378046

Citations 14

Authors

Gui-Qi Zhu

Ke-Qing Shi

Gui-Qian Huang

Li-Ren Wang

Yi-Qian Lin

Martin Braddock

Yong-Ping Chen

Meng-Tao Zhou

Ming-Hua Zheng

Affiliations

Soon will be listed here.

Abstract

Objectives: Therapies for treatment of patients with primary sclerosing cholangitis (PSC) include administration of ursodeoxycholic acid (UDCA) alone, or combination with metronidazole (MTZ) or mycophenolate mofetil (MMF), respectively. However, the optimum regimen still remains inconclusive. We aimed to compare interventions in terms of patient mortality or liver transplantation (MOLT), progression of liver histological stage (POLHS), serum bilirubin, alkaline phosphatase (ALP) levels and adverse events (AE).

Methods: We searched PubMed, Embase and the Cochrane Library for randomized controlled trials until 31, Jan 2015. We estimated hazard ratios (HRs), odds ratios (ORs) and mean difference (MD) between treatments on clinical outcomes. Sensitivity analyses based on the dose of UDCA, quality of trials or treatment duration were also performed.

Results: Ten RCTs were included. Compared with UDCA plus MTZ, UDCA (HR 0.28, 95%CI 0.01-3.41), UDCA plus MMF (HR 0.08, 95%CI 0.00-4.18), or OBS (HR 0.28, 95%CI 0.01-3.98) all provided an increased risk of MOLT. UDCA provided a significant reduction in bilirubin and ALP levels compared with OBS (MD -13.92, P < 0.001; MD -484.34, P < 0.001; respectively). With respect to POLHS, although differing not significantly, UDCA plus MTZ had a tendency to improve LHS more than UDCA (OR 1.33), UDCA plus MMF (OR 3.24) or OBS (OR 1.08). Additionally, UDCA plus MTZ (MD -544.66, P < 0.001) showed a significant reduction in ALP levels compared with OBS, but appeared to be associated with more AEs compared with UDCA (OR 5.09), UDCA plus MMF (OR 4.80) or OBS (OR 7.21).

Conclusions: MTZ plus UDCA was the most effective therapy in survival rates and liver histological progression.

Citing Articles

An overview of recent treatment options for primary sclerosing cholangitis.

Mousavere I, Kalampokis G, Fousekis F, Karayiannis P, Baltayiannis G, Christodoulou D Ann Gastroenterol. 2023; 36(6):589-598.

PMID: 38023975 PMC: 10662072. DOI: 10.20524/aog.2023.0834.

Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.

Kasztelan-Szczerbinska B, Rycyk-Bojarzynska A, Szczerbinska A, Cichoz-Lach H Nutrients. 2023; 15(3).

PMID: 36771465 PMC: 9921714. DOI: 10.3390/nu15030760.

Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.

Tanaka T, Sakai A, Tsujimae M, Yamada Y, Kobayashi T, Masuda A World J Gastroenterol. 2022; 28(28):3732-3738.

PMID: 36161046 PMC: 9372812. DOI: 10.3748/wjg.v28.i28.3732.

Effect of Different Ratios of Yinchen and Gancao Decoction on ANIT-Treated Cholestatic Liver Injury in Mice and Its Potential Underlying Mechanism.

Su H, Wang Q, Li Y, Jin J, Tan B, Yan D Front Pharmacol. 2021; 12:611610.

PMID: 33935705 PMC: 8082238. DOI: 10.3389/fphar.2021.611610.

Suppression of systemic inflammation and signs of acute and chronic cholangitis by multi-kinase inhibitor 1-(4-Cl-benzyl)-3-chloro-4-(CF3-phenylamino)-1H-pyrrole-2,5-dione.

Kuznietsova H, Byelinska I, Dziubenko N, Lynchak O, Milokhov D, Khilya O Mol Cell Biochem. 2021; 476(8):3021-3035.

PMID: 33792809 DOI: 10.1007/s11010-021-04144-y.

References

Ades A, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N . Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006; 24(1):1-19. DOI: 10.2165/00019053-200624010-00001. View

Shi J, Li Z, Zeng X, Lin Y, Xie W . Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res. 2009; 39(9):865-73. DOI: 10.1111/j.1872-034X.2009.00527.x. View

Angulo P, Batts K, Jorgensen R, LaRusso N, Lindor K . Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2000; 95(9):2333-7. DOI: 10.1111/j.1572-0241.2000.02323.x. View

Van Thiel D, Carroll P, Abu-Elmagd K, Irish W, McMichael J, Starzl T . Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995; 90(3):455-9. PMC: 2982698. View

Triantos C, Koukias N, Nikolopoulou V, Burroughs A . Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011; 34(8):901-10. DOI: 10.1111/j.1365-2036.2011.04822.x. View

Sinakos E, Marschall H, Kowdley K, Befeler A, Keach J, Lindor K . Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology. 2010; 52(1):197-203. PMC: 2928060. DOI: 10.1002/hep.23631. View

de Maria N, Colantoni A, Rosenbloom E, Van Thiel D . Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology. 1996; 43(12):1472-9. View

Wagner A . Azathioprine treatment in primary sclerosing cholangitis. Lancet. 1971; 2(7725):663-4. DOI: 10.1016/s0140-6736(71)80107-1. View

Angulo P, Lindor K . Primary sclerosing cholangitis. Hepatology. 1999; 30(1):325-32. DOI: 10.1002/hep.510300101. View

10.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. DOI: 10.1016/j.ijsu.2010.02.007. View

11.

Chapman R, Fevery J, Kalloo A, Nagorney D, Boberg K, Shneider B . Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51(2):660-78. DOI: 10.1002/hep.23294. View

12.

Othman M, Dunkelberg J, Roy P . Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review. Arab J Gastroenterol. 2012; 13(3):103-10. DOI: 10.1016/j.ajg.2012.06.011. View

13.

Chen W, Liu J, Gluud C . Bile acids for viral hepatitis. Cochrane Database Syst Rev. 2003; (2):CD003181. DOI: 10.1002/14651858.CD003181. View

14.

Mahdavinia M, Mirsaeidi M, Bishehsari F, McGrath K . Primary sclerosing cholangitis in common variable immune deficiency. Allergol Int. 2015; 64(2):187-9. PMC: 4386066. DOI: 10.1016/j.alit.2014.09.003. View

15.

Beuers U, Spengler U, Kruis W, Aydemir U, WIEBECKE B, Heldwein W . Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992; 16(3):707-14. DOI: 10.1002/hep.1840160315. View

16.

Wiesner R . Current concepts in primary sclerosing cholangitis. Mayo Clin Proc. 1994; 69(10):969-82. DOI: 10.1016/s0025-6196(12)61822-9. View

17.

Farkkila M, Karvonen A, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P . Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004; 40(6):1379-86. DOI: 10.1002/hep.20457. View

18.

Gordon F . Primary sclerosing cholangitis. Surg Clin North Am. 2008; 88(6):1385-407, x. DOI: 10.1016/j.suc.2008.07.010. View

19.

Lee M . On the Complexity of Additive Clustering Models. J Math Psychol. 2001; 45(1):131-148. DOI: 10.1006/jmps.1999.1299. View

20.

Arnelo U, von Seth E, Bergquist A . Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis. Endoscopy. 2015; 47(8):696-702. DOI: 10.1055/s-0034-1391845. View